Catalin Mihalcioiu

Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma.

J Clin Oncol 2020 Nov 30;38(33):3937-3946. Epub 2020 Sep 30.

Princess Alexandra Hospital, Woolloongabba, and Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.

View Article and Find Full Text PDF

November 2020

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.

Authors:

Ali Mehdi Mikhael Attias Niaz Mahmood Ani Arakelian Catalin Mihalcioiu Ciriaco A Piccirillo Moshe Szyf Shafaat Ahmed Rabbani

Front Oncol 2020 2;10:1361. Epub 2020 Sep 2.

Department of Medicine, McGill University, Montreal, QC, Canada.

View Article and Find Full Text PDF

September 2020

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.

Sci Rep 2020 09 7;10(1):14704. Epub 2020 Sep 7.

Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.

View Article and Find Full Text PDF

September 2020

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.

Mol Cancer Res 2019 12 19;17(12):2492-2507. Epub 2019 Sep 19.

Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.

View Article and Find Full Text PDF

December 2019

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

JAMA Oncol 2019 02;5(2):187-194

Princess Alexandra Hospital, University of Queensland, Woolloongabba, Queensland, Australia.

View Article and Find Full Text PDF

February 2019

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Authors:

Matthew Dankner Mathieu Lajoie Dan Moldoveanu Tan-Trieu Nguyen Paul Savage Shivshankari Rajkumar Xiu Huang Maria Lvova Alexei Protopopov Dana Vuzman David Hogg Morag Park Marie-Christine Guiot Kevin Petrecca Catalin Mihalcioiu Ian R Watson Peter M Siegel April A N Rose

Clin Cancer Res 2018 12 14;24(24):6483-6494. Epub 2018 Jun 14.

Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF

December 2018

DNA methylation signatures of breast cancer in peripheral T-cells.

Authors:

Surabhi Parashar David Cheishvili Niaz Mahmood Ani Arakelian Imrana Tanvir Haseeb Ahmed Khan Richard Kremer Catalin Mihalcioiu Moshe Szyf Shafaat A Rabbani

BMC Cancer 2018 May 18;18(1):574. Epub 2018 May 18.

Department of Medicine, McGill University Health Center, 1001 Décarie Blvd., Room EM1.3232, Montréal, QC, H4A3J1, Canada.

View Article and Find Full Text PDF

May 2018

Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab.

Authors:

James M Tsui Catalin Mihalcioiu Fabio L Cury

Cureus 2018 Feb 27;10(2):e2238. Epub 2018 Feb 27.

Department of Oncology, Division of Radiation Oncology, Cedars Cancer Centre / McGill University Health Centre, Montreal.

View Article and Find Full Text PDF

February 2018

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:

Niaz Mahmood Catalin Mihalcioiu Shafaat A Rabbani

Front Oncol 2018 12;8:24. Epub 2018 Feb 12.

Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

February 2018

The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.

Authors:

Adriana Aguilar-Mahecha Josiane Lafleur Manuela Pelmus Carole Seguin Cathy Lan Federico Discepola Bojan Kovacina Rosa Christodoulopoulos Ombretta Salvucci Catalin Mihalcioiu Josée-Anne Roy André Robidoux Elizabeth A Marcus Gerald Batist Mark Basik

Mod Pathol 2017 11 28;30(11):1567-1576. Epub 2017 Jul 28.

Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada.

View Article and Find Full Text PDF

November 2017

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.

Authors:

Stephen K Chia Susan L Ellard Mihaela Mates Stephen Welch Catalin Mihalcioiu Wilson H Miller Karen Gelmon Caroline Lohrisch Vikaash Kumar Sara Taylor Linda Hagerman Rachel Goodwin Tao Wang Shingo Sakashita Ming S Tsao Elizabeth Eisenhauer Penelope Bradbury

Breast Cancer Res 2017 05 2;19(1):54. Epub 2017 May 2.

Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.

View Article and Find Full Text PDF

May 2017

A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy.

Authors:

Philip Wong Ilana R Leppert David Roberge Karim Boudam Paul D Brown Thierry Muanza G Bruce Pike Jeffrey Chankowsky Catalin Mihalcioiu

Oncotarget 2016 08;7(32):50986-50996

Department of Oncology, McGill University Health Center, Montreal, Québec, Canada.

View Article and Find Full Text PDF

August 2016

A phase 2 study of tremelimumab in patients with advanced uveal melanoma.

Authors:

Anthony M Joshua Jose G Monzon Catalin Mihalcioiu David Hogg Michael Smylie Tina Cheng

Melanoma Res 2015 Aug;25(4):342-7

aDepartment of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario bDepartment of Medical Oncology, Tom Baker Cancer Centre, Calgary cDepartment of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta dDepartment of Medical Oncology, Royal Victoria Hospital, Montreal, Quebec, Canada.

View Article and Find Full Text PDF

August 2015

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.

Authors:

Anna Lisa Tedeschi Zohreh Eslami Evgenia Garoufalis Ramy R Saleh Atilla Omeroglu Gulbeyaz Altinel Maria Ait-Tihyaty Bertrand Jean-Claude Catalin Mihalcioiu

Onco Targets Ther 2015 21;8:911-9. Epub 2015 Apr 21.

Division of Medical Oncology, Department of Medicine, McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada.

View Article and Find Full Text PDF

May 2015

Nivolumab in previously untreated melanoma without BRAF mutation.

N Engl J Med 2015 Jan 16;372(4):320-30. Epub 2014 Nov 16.

The authors' affiliations are listed in the Appendix.

View Article and Find Full Text PDF

January 2015

Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review.

Authors:

Stefan Rodic Catalin Mihalcioiu Ramy R Saleh

Crit Rev Oncol Hematol 2014 Jul 24;91(1):74-92. Epub 2014 Jan 24.

Division of Medical Oncology, McGill University Health Centre, Montreal, Canada. Electronic address:

View Article and Find Full Text PDF

July 2014

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.

Authors:

Maria Ait-Tihyaty Zakaria Rachid Catalin Mihalcioiu Bertrand J Jean-Claude

Breast Cancer Res Treat 2012 May 14;133(1):217-26. Epub 2011 Sep 14.

Cancer Drug Research Laboratory, Department of Medicine, McGill University Health Center/Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada.

View Article and Find Full Text PDF

May 2012